Lifesome Therapeutics S.L

Startup

Lifesome Therapeutics is an innovative biotech start-up, founded in 2022 and based in Madrid, with a core team of 8 dedicated professionals. A biotech pioneering the future of personalized medicine through next-generation drug delivery systems. Supported by over 18 years of scientific expertise, its globally recognized team is focused on developing cutting-edge nanocarrier technologies for oncology, vaccines, antimicrobial therapies, and molecular biomarkers.

Its proprietary platform, Ohmline®, is engineered to revolutionize drug delivery by enhancing the precision and efficacy of targeted therapies. This versatile technology can encapsulate a wide array of therapeutics, from small molecules to biologics, providing powerful solutions for the treatment of complex diseases. Lifesome Therapeutics remains the sole owner of Ohmline technology and its applications. These are protected by 2 proprietary patents: PCTWO2011/101408A1 and PCTEP WO 2024/126812 A1.

Committed to accelerating clinical development and reducing drug development costs, Lifesome Therapeutics is positioned to drive significant advancements in precision medicine. Founded by Dr. Ana Bouchet (CEO), Professor Jean-Marie Ruysschaert (COO), and Professor Christophe Vandier (CTO), the mission is rooted in innovation and collaboration, with the goal of transforming patient care and shaping the future of healthcare.